NEW YORK, NY / ACCESSWIRE / August 17, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased NovoCure Limited ("NovoCure") (NASDAQ:NVCR) between January 5, 2023 and June 5, 2023.
If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/novocure-class-action-submission-form?prid=43731&wire=1
Allegations against NVCR include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company concealed the true nature of the LUNAR study data, including that the study relied on a relatively small percentage of study participants that had been receiving standard of care therapy; (ii) as a result, the data was materially less reliable in terms of demonstrating clinical efficacy; (iii) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company's regulatory prospects and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you suffered a loss in NovoCure you have until August 18, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/774858/NVCR-LAWSUIT-The-Law-Offices-of-Vincent-Wong-Notify-Investors-of-a-Class-Action-Lawsuit-Involving-NovoCure-Limited
